Literature DB >> 15023511

Borderline personality disorder in patients with bipolar disorder and response to lamotrigine.

Gilbert A Preston1, Barrie K Marchant, Fredrick W Reimherr, Robert E Strong, Dawson W Hedges.   

Abstract

BACKGROUND: Recent reports suggesting lamotrigine as an effective treatment in bipolar disorder, and perhaps borderline personality disorder, a common comorbid personality disorder in bipolar patients, led us to retrospectively examine patients from two bipolar studies to investigate this pattern of comorbidity, and to determine whether lamotrigine effected the dimensions of borderline personality.
METHODS: Fifteen months following entry into either study, we retrospectively assessed DSM-IV dimensions of borderline personality disorder pre- and post-treatment with lamotrigine in 35 bipolar patients.
RESULTS: Forty percent met criteria for borderline personality disorder; this subgroup had a more frequent history of substance abuse and childhood symptoms of attention deficit hyperactivity disorder (ADHD). Dimensions of borderline personality improved significantly with treatment in both patient groups, and corresponded with response of bipolar symptoms. Six (43%) comorbid bipolar patients endorsed three or fewer criteria of borderline personality during treatment with lamotrigine. There was a trend for comorbid bipolar patients to require a second psychoactive medication in addition to lamotrigine during extended treatment. LIMITATIONS: Criteria for borderline personality and improvement were assessed retrospectively in an open manner.
CONCLUSIONS: Dimensions of borderline personality disorder may respond to lamotrigine in comorbid bipolar patients; controlled studies appear warranted. Bipolar studies should assess and specify the number of patients with personality disorders in the trial.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15023511     DOI: 10.1016/S0165-0327(02)00358-0

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  16 in total

1.  Asenapine in the management of impulsivity and aggressiveness in bipolar disorder and comorbid borderline personality disorder: an open-label uncontrolled study.

Authors:  Andrea Aguglia; Ludovico Mineo; Alessandro Rodolico; Maria S Signorelli; Eugenio Aguglia
Journal:  Int Clin Psychopharmacol       Date:  2018-05       Impact factor: 1.659

2.  Personality disorder symptom severity predicts onset of mood episodes and conversion to bipolar I disorder in individuals with bipolar spectrum disorder.

Authors:  Tommy H Ng; Taylor A Burke; Jonathan P Stange; Patricia D Walshaw; Rachel B Weiss; Snezana Urosevic; Lyn Y Abramson; Lauren B Alloy
Journal:  J Abnorm Psychol       Date:  2017-04

3.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

Review 4.  Treatment for comorbid borderline personality disorder and alcohol use disorders: a review of the evidence and future recommendations.

Authors:  Mayumi O Gianoli; J Serrita Jane; Erin O'Brien; Elizabeth Ralevski
Journal:  Exp Clin Psychopharmacol       Date:  2012-06-11       Impact factor: 3.157

Review 5.  Problematic boundaries in the diagnosis of bipolar disorder: the interface with borderline personality disorder.

Authors:  Mark Zimmerman; Theresa A Morgan
Journal:  Curr Psychiatry Rep       Date:  2013-12       Impact factor: 5.285

Review 6.  HCN Channel Targets for Novel Antidepressant Treatment.

Authors:  Stacy M Ku; Ming-Hu Han
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

Review 7.  Efficacy and tolerability of pharmacotherapies for borderline personality disorder.

Authors:  Silvio Bellino; Erika Paradiso; Filippo Bogetto
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  Efficacy and Tolerability of Lamotrigine in Borderline Personality Disorder: A Systematic Review and Meta-Analysis.

Authors:  Mehak Pahwa; Nicolas A Nuñez; Boney Joseph; Ashok Seshadri; Danielle J Gerberi; Mark A Frye; Balwinder Singh
Journal:  Psychopharmacol Bull       Date:  2020-09-14

9.  The role of lamotrigine in the management of bipolar disorder.

Authors:  Felicity Ng; Karen Hallam; Nellie Lucas; Michael Berk
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

10.  Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.

Authors:  G M Goodwin; P M Haddad; I N Ferrier; J K Aronson; Trh Barnes; A Cipriani; D R Coghill; S Fazel; J R Geddes; H Grunze; E A Holmes; O Howes; S Hudson; N Hunt; I Jones; I C Macmillan; H McAllister-Williams; D R Miklowitz; R Morriss; M Munafò; C Paton; B J Saharkian; Kea Saunders; Jma Sinclair; D Taylor; E Vieta; A H Young
Journal:  J Psychopharmacol       Date:  2016-03-15       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.